{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-005427","form_type":"8-K","ticker":"ASBP","cik":"0001847345","company_name":"Aspire Biopharma Holdings, Inc.","filed_at":"2025-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.122714+00:00","generated_at":"2026-05-23T11:13:35.794060+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aspire Biopharma receives Nasdaq delisting notices for MVLS below $50M and bid price under $1.00","bullets":["Received two letters on April 16, 2025: MVLS deficiency (below $50M for 30 consecutive days) and bid price deficiency (below $1.00).","Company has 180 days until October 13, 2025 to regain compliance with MVLS; must achieve at least $50M for 10 consecutive business days.","Bid Price Rule allows 180-day compliance period; failure may lead to delisting or transfer to Nasdaq Capital Market.","Company is evaluating potential responses but has not decided on actions; no assurance of regaining compliance.","Tickers affected: ASBP (common stock) and ASBPW (warrants), both on Nasdaq Global Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-005427","json":"https://secwatch.observer/filing/0001641172-25-005427.json","markdown":"https://secwatch.observer/filing/0001641172-25-005427.md","text":"https://secwatch.observer/filing/0001641172-25-005427.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847345/000164117225005427/0001641172-25-005427-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847345/000164117225005427/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T11:13:35.794060+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b532d7d04ce967da9d28313e7e3ccd376a088c03","claim":"Aspire Biopharma Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"April 16, 2025, Aspire Biopharma Holdings, Inc. (the “Company”), received two letters from the Nasdaq Stock Exchange LLC (“Nasdaq”), each addressing a separate compliance deficiency under the Nasdaq Listing Rules. The first letter notified of the deficiency with regard to Rule 5450(b)(2)(A) (the “MVLS Notice”), which requires a company, whose securities are listed on The Nasdaq Global Market under the “Market Value Standard”, to maintain a minimum Market Value of Listed Securities (an “MVLS”) of $50,000,000. The deficiency was caused by the Company’s MVLS having been below the minimum level fo","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000164117225005427/0001641172-25-005427-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"cd76f50daa4b28e744f6cccd9750614bda657e58","claim":"Aspire Biopharma Holdings, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).","evidence_excerpt":"April 16, 2025, Aspire Biopharma Holdings, Inc. (the “Company”), received two letters from the Nasdaq Stock Exchange LLC (“Nasdaq”), each addressing a separate compliance deficiency under the Nasdaq Listing Rules. The first letter notified of the deficiency with regard to Rule 5450(b)(2)(A) (the “MVLS Notice”), which requires a company, whose securities are listed on The Nasdaq Global Market under the “Market Value Standard”, to maintain a minimum Market Value of Listed Securities (an “MVLS”) of $50,000,000. The deficiency was caused by the Company’s MVLS having been below the minimum level fo","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000164117225005427/0001641172-25-005427-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5450(b)(2)(A), 5810(c)(3)(C)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}